Unexpected finding points to potential way to stop macular degeneration
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight. The finding may allow doctors to halt the inflammation early on, potentially saving patients from blindness.
“Almost 200 million people in the world have macular degeneration. If macular degeneration were a country, it would be the eighth most populated nation in the world. That’s how large a problem this is,” said Jayakrishna Ambati, MD, vice chairman for research of UVA’s Department of Ophthalmology and the founding director of UVA’s Center for Advanced Vision Science. “For the first time, we know in macular degeneration what is one of the very first events that triggers the system to get alarmed and start, to use an anthropomorphic term, hyperventilating. This overdrive of inflammation is what ultimately damages cells, and so, potentially, we have a way of interfering very early in the process.”
Potential New Treatment for Macular Degeneration
Ambati and Nagaraj Kerur, PhD, assistant professor in the Department of Ophthalmology, and their laboratories have determined that the culprit is an enzyme called cGAS. The enzyme plays an important role in the body’s immune response to infections by detecting foreign DNA. But the molecule’s newly identified role in the “dry” form of age-related macular degeneration comes as wholly unexpected.
“It’s really surprising that in macular degeneration, which, as far as we know, has nothing to do with viruses or bacteria, that cGAS is activated, and that this alarm system is turned on,” Ambati said. “This is what leads to the killing of the cells in the retina, and, ultimately, vision loss.”
The researchers noted that cGAS may be an alarm not just for pathogens but for other harmful problems that warrant responses from the immune system. The enzyme may also play important roles in conditions such as diabetes, lupus and obesity, and researchers already are working to create drugs that could inhibit its function. “Because the target we’re talking about is an enzyme, we could develop small molecules that could block it,” Kerur said. “There are many drugs already on the market that target specific enzymes, such as the statins [which are used to lower cholesterol levels.]”
The promising new lead comes as good news for researchers seeking to develop new treatments for dry macular degeneration, as clinical trials in recent years have come to dead end after dead end.
The UVA researchers expect the development of a drug to inhibit cGAS will take several years, and that drug would then need to go through extensive testing to determine its safety and effectiveness for combating macular degeneration.
The researchers also hope to develop a way to detect the levels of the enzyme in patients’ eyes. That would let them determine when best to administer a treatment that blocks cGAS. “If they have high levels of this enzyme in their eye, they might be a wonderful candidate for this sort of treatment,” Ambati said. “This is really precision medicine at the single-molecule level.”
The Latest on: Macular degeneration
- Preventing and Treating Macular Degeneration in the Elderlyon July 19, 2019 at 10:47 am
Age-related macular degeneration (AMD) tops the list as one of the top three conditions that cause vision loss in people over the age of 60. AMD is most likely to affect seniors due to the slow ... […]
- Managed Care Opportunities and Approaches to Supporting Appropriate Selection of Treatment for Sight Preventionon July 19, 2019 at 8:51 am
Currently, up to 11 million people in the United States have some form of age-related macular degeneration (AMD), which is one of the leading causes of vision loss in older Americans. Ophthalmologists ... […]
- Review of Neovascular Age-Related Macular Degeneration Treatment Optionson July 19, 2019 at 8:51 am
Due to an aging population, visual impairment from neovascular age-related macular degeneration (nAMD) is increasing in the United States. Despite unprecedented improvements in vision preservation ... […]
- Yellow lenses to the rescue for macular degenerationon July 18, 2019 at 10:00 pm
Dear Dr. Roach • I have an elderly friend who’s becoming blind from macular degeneration. After hearing of a particularly frustrating event she experienced due to vision loss, I remembered the great ... […]
- Notal Vision Diagnostic Clinic reports completion of 6 million ForeseeHome AMD home-monitoring testson July 18, 2019 at 5:34 pm
the first FDA-cleared home-monitoring device for patients with intermediate dry Age-related Macular Degeneration (AMD) at risk for developing wet AMD. ForeseeHome uses a patented technology ... […]
- Enrollment complete in trial of Port Delivery System with ranibizumabon July 18, 2019 at 5:45 am
Patient enrollment has been completed in a phase 3 trial of the Port Delivery System with ranibizumab for wet age-related macular degeneration, Genentech and Roche announced. The randomized, ... […]
- Pixium Vision announced sustained success of its PRIMA System after 12-months in dry age-related macular degeneration patientson July 17, 2019 at 10:02 pm
Data confirm better than expected interim six-month results The system is sustainably well tolerated while preserving residual peripheral vision Some patients improve their ability to identify letters ... […]
- How to design a safe home for people with wet age-related macular degenerationon July 16, 2019 at 10:58 am
"GMA" sponsor Novartis and Nate Berkus share tips for how to design a safe home for people with the disease that can cause blurred vision and often lead to blindness. ... […]
- New laser shows promise in treating macular degenerationon July 15, 2019 at 1:35 pm
MEDFORD, Ore. (KOBI) — A breakthrough treatment for macular degeneration is being used on patients in the Rogue Valley. The Medford office using it is believed to be the only one West of the ... […]
- Specsavers Napier is putting a spotlight on macular degenerationon July 12, 2019 at 11:26 am
A Hawke's Bay optometrist is calling on locals to have an important conversation about their family's history of eye health. Specsavers Napier optometrist Scott Charlton is placing a spotlight on ... […]
via Google News and Bing News